Corporate Profile
ANTI-INFECTIVE COMPOUNDS EFFECTIVE AGAINST BACTERIA, VIRUSES AND FUNGI
NovaBay Pharmaceuticals is a clinical-stage biotechnology company focused on developing its proprietary and patented Aganocide® compounds. Aganocides are novel, broad-spectrum, fast-acting, synthetic anti-infectives designed to mimic the body's defense against infection. They are active against bacteria, fungi and viruses, and are being developed to treat and prevent a wide range of local, non-systemic infections with a low likelihood of developing bacterial resistance.
NOVABAY'S FOUR BUSINESS UNITS
NovaBay is focusing its technology on four distinct therapeutic areas: dermatology, ophthalmology, urology and hospital infections. In dermatology, the focus is on developing NVC-422 gel for impetigo and acne. NovaBay has the advantage of being partnered with Galderma, the leading dermatology company in the world. In ophthalmology, the company anticipates continuing its development of NVC-422 for the treatment of adenoviral conjunctivitis to confirm the encouraging results shown for epidemic keratoconjunctivitis (EKC) seen in the adenoviral conjunctivitis trial. In urology, NovaBay aims to reduce the incidence of urinary catheter blockage and encrustation (UCBE) and the associated urinary tract infections with an irrigation solution containing NVC-422. In hospital infection, NovaBay is targeting the six-million-patient market of chronic non-healing wounds, such as pressure, venous stasis and diabetic ulcers with its proprietary wound cleansing solution containing pure hypochlourus acid solution, NeutroPhase®, which has received two 510(k) clearances from the Food and Drug Administration.
COLLABORATION WITH GALDERMA
NovaBay has entered into and recently expanded an agreement with Galderma S.A. to develop and commercialize Aganocide compounds in acne, impetigo and other dermatological indications.
Investor Overview
NovaBay Pharmaceuticals is a clinical stage biotechnology company focused on developing its proprietary and patented topical Aganocide® compounds, which are novel, synthetic anti-infective product candidates with equivalent activity to the active antimicrobial molecules generated within white blood cells. NovaBay's topical Aganocide compounds are being developed to treat and prevent a wide range of infections without causing bacterial resistance. NovaBay has internal development programs aimed at addressing hospital infections, chronic non-healing wounds, UCBE and onychomycosis.
NovaBay has entered into and recently expanded an agreement with Galderma S.A. to develop and commercialize Aganocide compounds in acne, impetigo and other dermatological indications.
Transfer Agent
The transfer agent and registrar for our common stock is Computershare Trust Company, N.A. with the following contact information:
For standard US postal mail
Computershare Trust Company, N.A.
Po Box 43070
Providence, RI 02940-3070
For overnight/express delivery
Computershare Trust Company, N.A.
250 Royall Street
Canton, MA 02021
For DWAC instructions provided to brokers
FAST Transfer Agent number - 50173
Telephone and Fax
Toll free in the US +1 800 962 4284
Telephone +1 303-262-0600
Fax +1 303-262-0700
Website
www.computershare.com
eMail inquiries
web.queries@computershare.com
Investor Relations contacts
Theresa Granados
(510) 899-8870
Email Theresa
Shares Outstanding - 28,916,562 a/o - Mar 16, 2012
2012 Outside News Sources
Publish Date - Headline
Apr 5, 2012 NovaBay Pharmaceuticals Launches CEO Blog
Mar 20, 2012 NovaBay Pharmaceuticals Signs Option Agreement with Virbac Animal Health for Aganocide(R) Compounds
Mar 20, 2012 NovaBay Set for " Phenomenal Year" With Key Upcoming Clinical Data Announcements and Partnership Developments
Mar 6, 2012 NovaBay Pharmaceuticals to Present at Two Upcoming Investor Conferences in March
Feb 29, 2012 NovaBay Issues Statement Regarding Market Activity
Feb 8, 2012 NovaBay Pharmaceuticals to Present at the 14th Annual BIO CEO & Investor Conference
Feb 7, 2012 NovaBay Pharmaceuticals to Hold Conference Call to Provide Year-End Business Update and 2012 Outlook
Jan 23, 2012 NovaBay Prepares to Launch Global Phase 2b Ophthalmic Study of NVC-422
Jan 9, 2012 NovaBay Pharmaceuticals Announces Strategic Marketing Agreement for NeutroPhase in China
SEC Transaction Summary - Last 6 Months
Buy/Sell
Buys 2 - Sells 0 - Total 2
Shares Bought 90,000 - Sold 0 - Gross 90,000 - Net 90,000
